{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:09:01Z","timestamp":1789459741444,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ohio State University College of Medicine Roessler research scholarship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Pancreatic adenosquamous carcinoma (PASC) is a rare and aggressive form of pancreatic cancer whose management often follows its more common pancreatic ductal adenocarcinoma (PDAC) counterpart. While neoadjuvant therapy (NT) is increasingly utilized prior to surgery for PDAC, whether patients with PASC experience similar benefits is unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using the National Cancer Database (NCDB), all patients with stage I-III PASC who underwent surgical resection between 2006 and 2020 were included. Patient and tumor characteristics and overall survival (OS) of patients who underwent surgery first (SF) were compared to those who received NT prior to surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 1191 patients with PASC who underwent curative intent resection, 208 (17.5%) received NT, whereas 983 (82.5%) underwent SF. Overall, NT was associated with improved OS compared with an SF approach (median 20.7 vs 15.9\u00a0months; <jats:italic>p<\/jats:italic>\u2009=\u20090.03). On multivariable Cox regression analysis, factors independently associated with improved OS included treatment at an academic\/research facility, receipt of NT, and receipt of adjuvant therapy. Factors associated with decreased OS included Black race, positive surgical margins, worse comorbidity score, and higher\u00a0cancer stage. There was no significant difference in OS between patients who received NT chemotherapy and radiation vs NT chemotherapy alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Among patients with localized PASC, the receipt of NT prior to surgical resection was associated with improved OS outcomes. Future research is needed to clarify the optimal neoadjuvant treatment regimen, including the role of preoperative radiation, to enhance response to therapy and improve long-term outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12029-025-01269-x","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:47:05Z","timestamp":1751420825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of Neoadjuvant Therapy for Patients with Adenosquamous Carcinoma of the Pancreas: Outcomes from the National Cancer Database"],"prefix":"10.1007","volume":"56","author":[{"given":"Amanda K.","family":"Walsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamantis I.","family":"Tsilimigras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex B.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Manne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafia","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Pitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Cloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"1269_CR1","first-page":"75","volume":"6","author":"CG Simone","year":"2013","unstructured":"Simone CG, Zuluaga Toro T, Chan E, Feely MM, Trevino JG, George TJ. Characteristics and outcomes of adenosquamous carcinoma of the pancreas. Gastrointest Cancer Res GCR. 2013;6:75\u20139.","journal-title":"Gastrointest Cancer Res GCR"},{"key":"1269_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7812\/TPP\/22.095","volume":"27","author":"HV Kwak","year":"2022","unstructured":"Kwak HV, Hsu DS, Chang A, Kazantsev GB, Peng PD, Spitzer AL, Chang C-K. Pancreatic adenosquamous carcinoma: Experience within an integrated health care system. Perm J. 2022;27:9\u201312. https:\/\/doi.org\/10.7812\/TPP\/22.095.","journal-title":"Perm J"},{"key":"1269_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jss.2011.06.015","volume":"174","author":"CA Boyd","year":"2012","unstructured":"Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS. 415 Patients with adenosquamous carcinoma of the pancreas: A population-based analysis of prognosis and survival. J Surg Res. 2012;174:12\u20139. https:\/\/doi.org\/10.1016\/j.jss.2011.06.015.","journal-title":"J Surg Res"},{"key":"1269_CR4","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.3390\/cancers14163946","volume":"14","author":"R Braun","year":"2022","unstructured":"Braun R, Klinkhammer-Schalke M, Zeissig SR, Kleihus van Tol K, Bolm L, Honselmann KC, Petrova E, Lapshyn H, Deichmann S, Abdalla TSA, Heckelmann B, Bronsert P, Zemskov S, Hummel R, Keck T, Wellner UF. Clinical outcome and prognostic factors of pancreatic adenosquamous carcinoma compared to ductal adenocarcinoma\u2014Results from the German Cancer Registry Group. Cancers. 2022;14:3946. https:\/\/doi.org\/10.3390\/cancers14163946.","journal-title":"Cancers"},{"key":"1269_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1031","volume":"4","author":"CT Aquina","year":"2021","unstructured":"Aquina CT, Ejaz A, Tsung A, Pawlik TM, Cloyd JM. National trends in the use of neoadjuvant therapy before cancer surgery in the US From 2004 to 2016. JAMA Netw Open. 2021;4: e211031. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.1031.","journal-title":"JAMA Netw Open"},{"key":"1269_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.6004\/jnccn.2019.7380","volume":"18","author":"JM Cloyd","year":"2020","unstructured":"Cloyd JM, Shen C, Santry H, Bridges J, Dillhoff M, Ejaz A, Pawlik TM, Tsung A. Disparities in the use of neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma. J Natl Compr Cancer Netw JNCCN. 2020;18:556\u201363. https:\/\/doi.org\/10.6004\/jnccn.2019.7380.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"1269_CR7","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s11605-011-1659-7","volume":"15","author":"JM Laurence","year":"2011","unstructured":"Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VWT, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2011;15:2059\u201369. https:\/\/doi.org\/10.1007\/s11605-011-1659-7.","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"key":"1269_CR8","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2016.67.5561","volume":"34","author":"EP Balaban","year":"2016","unstructured":"Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:2654\u201368. https:\/\/doi.org\/10.1200\/JCO.2016.67.5561.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1269_CR9","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"Sauer R, Becker H, Hohenberger W, R\u00f6del C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens J-H, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, R\u00f6del C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens J-H, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731\u201340. https:\/\/doi.org\/10.1056\/NEJMoa040694.","journal-title":"N Engl J Med"},{"key":"1269_CR10","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1245\/s10434-019-07602-6","volume":"26","author":"AM Altman","year":"2019","unstructured":"Altman AM, Wirth K, Marmor S, Lou E, Chang K, Hui JYC, Tuttle TM, Jensen EH, Denbo JW. Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival. Ann Surg Oncol. 2019;26:4108\u201316. https:\/\/doi.org\/10.1245\/s10434-019-07602-6.","journal-title":"Ann Surg Oncol"},{"key":"1269_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jamcollsurg.2006.12.011","volume":"204","author":"TE Aloia","year":"2007","unstructured":"Aloia TE, Lee JE, Vauthey J-N, Abdalla EK, Wolff RA, Varadhachary GR, Abbruzzese JL, Crane CH, Evans DB, Pisters PWT. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg. 2007;204:347\u201355. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2006.12.011.","journal-title":"J Am Coll Surg"},{"key":"1269_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.hpb.2019.07.008","volume":"22","author":"DK DePeralta","year":"2020","unstructured":"DePeralta DK, Ogami T, Zhou J-M, Schell MJ, Powers BD, Hodul PJ, Malafa MP, Fleming JB. Completion of adjuvant therapy in patients with resected pancreatic cancer. HPB. 2020;22:241\u20138. https:\/\/doi.org\/10.1016\/j.hpb.2019.07.008.","journal-title":"HPB"},{"key":"1269_CR13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/jcm9041129","volume":"9","author":"JM Cloyd","year":"2020","unstructured":"Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A, Williams T, Abushahin L, Bridges JFP, Santry H. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020;9:1129. https:\/\/doi.org\/10.3390\/jcm9041129.","journal-title":"J Clin Med"},{"key":"1269_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer D, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:157\u201368. https:\/\/doi.org\/10.1016\/S2468-1253(22)00348-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1269_CR15","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1002\/jso.26435","volume":"123","author":"M Guo","year":"2021","unstructured":"Guo M, Beal EW, Miller ED, Williams TM, Tsung A, Dillhoff M, Ejaz A, Pawlik TM, Cloyd JM. Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score-matched analysis of the NCDB. J Surg Oncol. 2021;123:1558\u201367. https:\/\/doi.org\/10.1002\/jso.26435.","journal-title":"J Surg Oncol"},{"key":"1269_CR16","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1245\/s10434-017-5777-7","volume":"24","author":"JM Cloyd","year":"2017","unstructured":"Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey J-N, Fleming JB, Lee JE, Katz MHG. Influence of preoperative therapy on short- and long-term outcomes of patients with adenocarcinoma of the ampulla of vater. Ann Surg Oncol. 2017;24:2031\u20139. https:\/\/doi.org\/10.1245\/s10434-017-5777-7.","journal-title":"Ann Surg Oncol"},{"key":"1269_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.amjsurg.2018.08.024","volume":"218","author":"JM Cloyd","year":"2019","unstructured":"Cloyd JM, Prakash L, Vauthey J-N, Aloia TA, Chun YS, Tzeng C-W, Kim MP, Lee JE, Katz MHG. The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. Am J Surg. 2019;218:145\u201350. https:\/\/doi.org\/10.1016\/j.amjsurg.2018.08.024.","journal-title":"Am J Surg"},{"key":"1269_CR18","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.surg.2022.03.009","volume":"172","author":"SR Kaslow","year":"2022","unstructured":"Kaslow SR, Prendergast K, Vitiello GA, Hani L, Berman RS, Lee AY, Correa-Gallego C. Systemic therapy for duodenal adenocarcinoma: An analysis of the National Cancer Database (NCDB). Surgery. 2022;172:358\u201364. https:\/\/doi.org\/10.1016\/j.surg.2022.03.009.","journal-title":"Surgery"},{"key":"1269_CR19","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.surg.2020.11.026","volume":"169","author":"JJ Hue","year":"2021","unstructured":"Hue JJ, Katayama E, Sugumar K, Winter JM, Ammori JB, Rothermel LD, Hardacre JM, Ocuin LM. The importance of multimodal therapy in the management of nonmetastatic adenosquamous carcinoma of the pancreas: Analysis of treatment sequence and strategy. Surgery. 2021;169:1102\u20139. https:\/\/doi.org\/10.1016\/j.surg.2020.11.026.","journal-title":"Surgery"},{"key":"1269_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.humpath.2009.07.012","volume":"41","author":"KR Voong","year":"2010","unstructured":"Voong KR, Davison J, Pawlik TM, Uy MO, Hsu CC, Winter J, Hruban RH, Laheru D, Rudra S, Swartz MJ, Nathan H, Edil BH, Schulick R, Cameron JL, Wolfgang CL, Herman JM. Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol. 2010;41:113\u201322. https:\/\/doi.org\/10.1016\/j.humpath.2009.07.012.","journal-title":"Hum Pathol"},{"key":"1269_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The national cancer data base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683\u201390. https:\/\/doi.org\/10.1245\/s10434-007-9747-3.","journal-title":"Ann Surg Oncol"},{"key":"1269_CR22","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jamasurg.2018.0492","volume":"153","author":"RP Merkow","year":"2018","unstructured":"Merkow RP, Rademaker AW, Bilimoria KY. Practical guide to surgical data sets: National Cancer Database (NCDB). JAMA Surg. 2018;153:850\u20131. https:\/\/doi.org\/10.1001\/jamasurg.2018.0492.","journal-title":"JAMA Surg"},{"key":"1269_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/jso.26706","volume":"125","author":"ZJ Brown","year":"2022","unstructured":"Brown ZJ, Labiner HE, Shen C, Ejaz A, Pawlik TM, Cloyd JM. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma. J Surg Oncol. 2022;125:185\u201393. https:\/\/doi.org\/10.1002\/jso.26706.","journal-title":"J Surg Oncol"},{"key":"1269_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12029-025-01185-0","volume":"56","author":"CN Kersch","year":"2025","unstructured":"Kersch CN, Grossberg AJ. Perioperative radiation for patients with resectable pancreatic cancer: an updated review after the initial RTOG 0848 results. J Gastrointest Cancer. 2025;56:70. https:\/\/doi.org\/10.1007\/s12029-025-01185-0.","journal-title":"J Gastrointest Cancer"},{"key":"1269_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/bjs\/znac354","volume":"110","author":"ZJ Brown","year":"2022","unstructured":"Brown ZJ, Heh V, Labiner HE, Brock GN, Ejaz A, Dillhoff M, Tsung A, Pawlik TM, Cloyd JM. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Br J Surg. 2022;110:34\u201342. https:\/\/doi.org\/10.1093\/bjs\/znac354.","journal-title":"Br J Surg"},{"key":"1269_CR26","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.3390\/cancers15153967","volume":"15","author":"RC Chick","year":"2023","unstructured":"Chick RC, Gunderson AJ, Rahman S, Cloyd JM. Neoadjuvant immunotherapy for localized pancreatic cancer: challenges and early results. Cancers. 2023;15:3967. https:\/\/doi.org\/10.3390\/cancers15153967.","journal-title":"Cancers"},{"key":"1269_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.soi.2024.100102","volume":"1","author":"K Im","year":"2024","unstructured":"Im K, Kareddy N, Satyananda V, O\u2019Connor VV. Is pancreatic adenosquamous carcinoma (PASC) a surgical disease? A large healthcare system review. Surg Oncol Insight. 2024;1: 100102. https:\/\/doi.org\/10.1016\/j.soi.2024.100102.","journal-title":"Surg Oncol Insight"},{"key":"1269_CR28","doi-asserted-by":"publisher","unstructured":"Cloyd JM, Sarna A, Arango MJ, Bates SE, Bhutani MS, et al. Best practices for delivering neoadjuvant therapy in pancreatic ductal adenocarcinoma. JAMA Surg. 2025;160:172\u201380. https:\/\/doi.org\/10.1001\/jamasurg.2024.5191.","DOI":"10.1001\/jamasurg.2024.5191"},{"key":"1269_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12029-024-01123-6","volume":"56","author":"T Tatsuguchi","year":"2024","unstructured":"Tatsuguchi T, Kitahara D, Kozono S, Date K, Shinkawa T, Kuga H, Tamiya S, Nishihara K, Nakano T. Increased proportion of the squamous cell carcinoma components is associated with aggressive behavior and a worse prognosis in resected pancreatic adenosquamous carcinoma. J Gastrointest Cancer. 2024;56:5. https:\/\/doi.org\/10.1007\/s12029-024-01123-6.","journal-title":"J Gastrointest Cancer"},{"key":"1269_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.radonc.2021.03.017","volume":"159","author":"G Li","year":"2021","unstructured":"Li G, Jiang Y, Li G, Qiao Q. Comprehensive analysis of radiosensitivity in head and neck squamous cell carcinoma. Radiother Oncol. 2021;159:126\u201335. https:\/\/doi.org\/10.1016\/j.radonc.2021.03.017.","journal-title":"Radiother Oncol"},{"key":"1269_CR31","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00384-022-04198-4","volume":"37","author":"C Cheng","year":"2022","unstructured":"Cheng C, Luo Z, Xiong W, Shi Z, Tan H. Epidemiology and survival outcomes in adenosquamous carcinoma: a population-based study. Int J Colorectal Dis. 2022;37:1581\u201392. https:\/\/doi.org\/10.1007\/s00384-022-04198-4.","journal-title":"Int J Colorectal Dis"},{"key":"1269_CR32","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7099","volume":"22","author":"JM Cloyd","year":"2024","unstructured":"Cloyd JM, Colby S, Guthrie KA, Lowy AM, Chiorean EG, Philip P, Sohal D, Ahmad S. Failure to undergo resection following neoadjuvant therapy for resectable pancreatic cancer: a secondary analysis of SWOG S1505. J Natl Compr Cancer Netw JNCCN. 2024;22: e237099. https:\/\/doi.org\/10.6004\/jnccn.2023.7099.","journal-title":"J Natl Compr Cancer Netw JNCCN"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01269-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01269-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01269-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:47:06Z","timestamp":1751420826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01269-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1269"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01269-x","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"23 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the deidentified nature of the data, this research is considered exempt from IRB review and informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}